BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1376 related articles for article (PubMed ID: 25649494)

  • 1. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
    Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
    Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
    BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.
    Beheshti M; Imamovic L; Broinger G; Vali R; Waldenberger P; Stoiber F; Nader M; Gruy B; Janetschek G; Langsteger W
    Radiology; 2010 Mar; 254(3):925-33. PubMed ID: 20177103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer.
    Zattoni F; Agostini E; Cattaneo F; Maruzzo M; Basso U; Zattoni F; Evangelista L
    Clin Imaging; 2017; 43():110-116. PubMed ID: 28278446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading.
    Langsteger W; Balogova S; Huchet V; Beheshti M; Paycha F; Egrot C; Janetschek G; Loidl W; Nataf V; Kerrou K; Pascal O; Cussenot O; Talbot JN
    Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):448-57. PubMed ID: 21738117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement.
    Van den Bergh L; Lerut E; Haustermans K; Deroose CM; Oyen R; Isebaert S; Budiharto T; Ameye F; Mottaghy FM; Bogaerts K; Van Poppel H; Joniau S
    Urol Oncol; 2015 Mar; 33(3):109.e23-31. PubMed ID: 25655681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.
    Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
    BJU Int; 2012 Nov; 110(10):1501-6. PubMed ID: 22502982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer.
    Beauregard JM; Williams SG; Degrado TR; Roselt P; Hicks RJ
    J Med Imaging Radiat Oncol; 2010 Aug; 54(4):325-32. PubMed ID: 20718912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.
    Poulsen MH; Petersen H; Høilund-Carlsen PF; Jakobsen JS; Gerke O; Karstoft J; Steffansen SI; Walter S
    BJU Int; 2014 Dec; 114(6):818-23. PubMed ID: 24314065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.
    Budiharto T; Joniau S; Lerut E; Van den Bergh L; Mottaghy F; Deroose CM; Oyen R; Ameye F; Bogaerts K; Haustermans K; Van Poppel H
    Eur Urol; 2011 Jul; 60(1):125-30. PubMed ID: 21292388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pattern of occult nodal relapse diagnosed with (18)F-fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only radiotherapy.
    Lépinoy A; Cochet A; Cueff A; Cormier L; Martin E; Maingon P; Bosset JF; Brunotte F; Créhange G
    Radiother Oncol; 2014 Apr; 111(1):120-5. PubMed ID: 24780635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of [(18) F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer.
    Pinaquy JB; De Clermont-Galleran H; Pasticier G; Rigou G; Alberti N; Hindie E; Mokrane Y; Fernandez P
    Prostate; 2015 Feb; 75(3):323-31. PubMed ID: 25393215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.
    Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Loidl W; Broinger G; Stoiber F; Foglman I; Langsteger W
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1766-74. PubMed ID: 18465129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer.
    Husarik DB; Miralbell R; Dubs M; John H; Giger OT; Gelet A; Cservenyàk T; Hany TF
    Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):253-63. PubMed ID: 17926036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
    Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
    J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Metser U; Berlin A; Halankar J; Murphy G; Jhaveri KS; Ghai S; Tau N
    AJR Am J Roentgenol; 2018 Mar; 210(3):635-640. PubMed ID: 29323548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms.
    Schiavina R; Scattoni V; Castellucci P; Picchio M; Corti B; Briganti A; Franceschelli A; Sanguedolce F; Bertaccini A; Farsad M; Giovacchini G; Fanti S; Grigioni WF; Fazio F; Montorsi F; Rigatti P; Martorana G
    Eur Urol; 2008 Aug; 54(2):392-401. PubMed ID: 18456393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ¹⁸F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer.
    Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
    World J Urol; 2014 Aug; 32(4):965-70. PubMed ID: 24141889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer.
    Tuncel M; Souvatzoglou M; Herrmann K; Stollfuss J; Schuster T; Weirich G; Wester HJ; Schwaiger M; Krause BJ
    Nucl Med Biol; 2008 Aug; 35(6):689-95. PubMed ID: 18678354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.